S790 Risk of Neuroendocrine Neoplasms With Glucagon-Like-Petide-1 Receptor Agonist Use in Patients With Type 2 Diabetes Mellitus

Introduction: Prior studies demonstrate reduced risk of several malignancies among patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like-peptide-1 receptor agonists (GLP-1 RA). A recent study however found expression of GLP-1 RA among neuroendocrine neoplasm (NEN) cell lines and growth promotion in xenografts treated with semaglutide. In this study, we evaluate incidence of NENs among patients diagnosed as overweight/obese and patients with T2DM prescribed GLP-1 RA based drugs. Methods: The TriNetX database was utilized for this study. Incidence of NENs between patients with overweight/obesity were compared to a control group without obesity within 15 years following index diagnosis of obesity or, in the control group, a non-specific outpatient visit. Groups were matched for demographics, tobacco use, family malignancy history, alcohol use, and socioeconomic factors. In a separate analysis, incidence of NENs among patients with T2DM were compared between those prescribed GLP-1 RAs versus other antihyperglycemic agents (AHA) within 15 years following index prescription of GLP-1 RA or comparator AHA. Patients with exposure to the comparator AHA were excluded from their respective groups. A subgroup analysis was performed among patients with overweight/obesity. Exclusion criteria included Merkel cell carcinoma, multiple endocrine neoplasia type 1, Cushing’s syndrome, Von Hippel-Lindau syndrome, tuberous sclerosis, and prior NEN. Results: Patients with overweight/obesity had a significant increased risk of NENs when compared to the control group (3,840/794, 235 (0.48%) vs 2,785/794,235 (0.35%); RR: 1.38 (95% confidence interval 1.31-1.45), P < 0.0001). Among patients with T2DM, GLP-1 RA exposure was associated with significantly lower risk of NENs compared to insulin (70/31,171 (0.23%) vs 137/31,171 (0.44%); RR: 0.51 (0.38, 0.68), P < 0.0001), but no significant difference was appreciated with other AHAs. In the subset of patients with obesity/overweight, GLP-1 RAs were associated with decreased risk compared to insulin (43/15,230 (0.28%) vs 68/15,230 (0.45%); RR: 0.63 (0.43, 0.93), P = 0.02) and metformin (39/10,370 (0.38%) vs 64/10,370 (0.62%); RR: 0.61 (0.41, 0.91), P = 0.01). Conclusion: This study suggests obesity to be significantly associated with incidence of NENs. Furthermore, our findings do not demonstrate an increased incidence of NENs with GLP-1 RA use among patients with T2DM and show decreased risk when compared to insulin exposure.